Kelly E. Dooley

Department Affiliation: Primary: Medicine, Divisions of Clinical Pharmacology and Infectious Diseases; Secondary: Pharmacology and Molecular Sciences
Degree: M.D., Duke University; Ph.D., Johns Hopkins Bloomberg School of Public Health
Rank: Assistant Professor
Telephone Number: 410-287-0517
Fax Number: 410-614-9978
E-mail address: kdooley1@jhmi.edu
School of Medicine Address: Osler 508, 600 N. Wolfe Street, Baltimore, MD 21287

Clinical pharmacology of anti-infective agents; Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in pregnant co-infected women and the relationship between drug exposure and maternal and perinatal HIV outcomes. Other interests include evaluation of alternative strategies for treatment of HIV in patients who cannot take non-nucleoside reverse transcriptase inhibitors (resistance, intolerance) but require rifampin-based TB treatment; treatment of multidrug-resistant TB; and TB treatment in Morocco

Representative Publications:

Dooley, K.E., Golub, J., Goes, F.S., Merz, W.G., and Sterling, T.R. Empiric Treatment of Community-Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis. Clinical Infectious Diseases 34: 1607-12, 2002. Pub Med Reference
Dooley, K.E., Flexner, C., and Andrade, A.S. Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti-Infective Agents: Repercussions for Resource-Limited Countries. Journal of Infectious Diseases 198: 948-61, 2008. Pub Med Reference
Dooley, K.E., Flexner, C., Hackman, J., Peloquin, C., Nuermberger, E., Chaisson, R.E., and Dorman, S.E. Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations. Antimicrobial Agents and Chemotherapy 52: 4037-42, 2008. Pub Med Reference
Ribiero, S., Dooley, K.E., Hackman, J., Loredo, C., Efron, A., Chaisson, R.E. Conde, M.B., Boechat, N., and Dorman, S.E. T-SPOT.TB Responses DuringTreatment of Pulmonary Tuberculosis. BMC Infectious Diseases 9: 23, 2009. Pub Med Reference
Dooley, K.E., Tang, T., Golub, J., Dorman, S.E., and Cronin, W. Imparct of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. American Journal of Tropical Medicine and Hygiene 80: 634-9, 2009. Pub Med Reference
Dooley, K.E. and Chaisson, R.E. Tuberculosis and Diabetes Mellitus: The Convergence of Two Epidemics. Lancet Infectious Diseases 9: 737-746, 2009. Pub Med Reference
Matteelli, A., Carvalho, A.C.C., Dooley, K.E., and Kritski, A. TMC207: the first compound of a new class of potent antituberculosis drugs. Future Medicine, 5: 849-58, 2010. Pub Med Reference
Almeida, D., Converse, P.J., Ahmad, Z., Dooley, K.E., Nuermberger, E.L., Grosset, J. Activities of rifampin, rifapentine and clarithromycin, alone and in combination, against Mycobacterium ulcerans disease in mice. PLoS Neglected Tropical Diseases, 5: e933, 2011. Pub Med Reference
Burman, W., Dooley, K.E., Nuermberger, E. The rifamycins: renewed interest in an old drug class. In Progress in Respiratory Research, Volume 40, Chapter title: "Antituberculosis Chemotherapy", edited by Peter Donald and Paul van Helden, Karger AG - Medical and Scientific Publishers.
Dooley, K.E., Lahlou, O., Ghali, I., Kudsen, J., Elmessaoudi, M.D., Cherkaoui, I., El Aouad, R. Risk Factors for Tuberculosis Treatment Failure, Default, or Relapse and Outcomes of Retreatment in Morocco. BMC Public Health 11:140, 2011. Pub Med Reference